Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Anavex price target raised to $80 from $40 at JonesTrading » 07:01
12/02/22
12/02
07:01
12/02/22
07:01
AVXL

Anavex

$8.85 /

+0.03 (+0.34%)

, ESALY

Eisai

$71.85 /

+1.75 (+2.50%)

, BIIB

Biogen

$302.00 /

-2.99 (-0.98%)

JonesTrading analyst…

JonesTrading analyst Soumit Roy raised the firm's price target on Anavex (AVXL) to $80 from $40 and keeps a Buy rating on the shares after the company announced the Phase 2b/3 trial of oral ANAVEX2-73, or blarcamesine, for the treatment of mild cognitive impairment due to Alzheimer's disease, AD, and mild AD met the primary endpoints. In Roy's view, there is "a clear win shown by ADAS-Cog" and "markedly better safety" with Anavex's oral drug than seen with Eisai (ESALY) and Biogen's (BIIB) antibody.

ShowHide Related Items >><<
ESALY Eisai
$71.85 /

+1.75 (+2.50%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

AVXL Anavex
$8.85 /

+0.03 (+0.34%)

AVXL Anavex
$8.85 /

+0.03 (+0.34%)

06/23/22 Berenberg
Anavex initiated with a Buy at Berenberg
02/02/22 Cantor Fitzgerald
Anavex price target lowered to $16 from $27 at Cantor Fitzgerald
ESALY Eisai
$71.85 /

+1.75 (+2.50%)

11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
11/29/22 Jefferies
Prothena data from AD/PD abstract 'promising,' says Jefferies
11/14/22 Jefferies
Biogen scarcity value goes up after Roche miss in Alzheimer's, says Jefferies
BIIB Biogen
$302.00 /

-2.99 (-0.98%)

12/01/22 Atlantic Equities
Biogen price target raised to $295 from $220 at Atlantic Equities
11/30/22 Wedbush
Biogen price target raised to $247 from $218 at Wedbush
BIIB Biogen
$302.00 /

-2.99 (-0.98%)

AVXL Anavex
$8.85 /

+0.03 (+0.34%)

ESALY Eisai
$71.85 /

+1.75 (+2.50%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

ESALY Eisai
$71.85 /

+1.75 (+2.50%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

AVXL Anavex
$8.85 /

+0.03 (+0.34%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

AVXL Anavex
$8.85 /

+0.03 (+0.34%)

Conference/Events
Mizuho healthcare analysts to hold an analyst/industry conference call » 04:55
12/02/22
12/02
04:55
12/02/22
04:55
ESALY

Eisai

$71.85 /

+1.75 (+2.50%)

, BIIB

Biogen

$302.00 /

-2.99 (-0.98%)

Healthcare Analysts,…

Healthcare Analysts, along with Drs. Solomon and Appleby, discuss the upcoming Clinical Trials in Alzheimer's Disease (CTAD) Meeting and Eisai and Biogen's Lecanemab in the second of two Analyst/Industry conference calls to be held on December 2.

ShowHide Related Items >><<
ESALY Eisai
$71.85 /

+1.75 (+2.50%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

ESALY Eisai
$71.85 /

+1.75 (+2.50%)

11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
11/29/22 Jefferies
Prothena data from AD/PD abstract 'promising,' says Jefferies
11/14/22 Jefferies
Biogen scarcity value goes up after Roche miss in Alzheimer's, says Jefferies
BIIB Biogen
$302.00 /

-2.99 (-0.98%)

12/01/22 Atlantic Equities
Biogen price target raised to $295 from $220 at Atlantic Equities
11/30/22 Wedbush
Biogen price target raised to $247 from $218 at Wedbush
BIIB Biogen
$302.00 /

-2.99 (-0.98%)

ESALY Eisai
$71.85 /

+1.75 (+2.50%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

ESALY Eisai
$71.85 /

+1.75 (+2.50%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

BIIB Biogen
$302.00 /

-2.99 (-0.98%)

Thursday
Recommendations
Biogen price target raised to $295 from $220 at Atlantic Equities » 06:42
12/01/22
12/01
06:42
12/01/22
06:42
BIIB

Biogen

$304.99 /

+13.525 (+4.64%)

Atlantic Equities analyst…

Atlantic Equities analyst Steve Chesney raised the firm's price target on Biogen to $295 from $220 and keeps a Neutral rating on the shares. The analyst is "encouraged" by the lecanemab full data presentation "given the consistency of the efficacy and lack of statistical wrinkles in the reported results." That said, the jury is still out on the overall clinical meaningfulness of the results, says Chesney, who expects lingering concerns on the safety profile given recent media reports.

ShowHide Related Items >><<
BIIB Biogen
$304.99 /

+13.525 (+4.64%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
11/30/22 Wedbush
Biogen price target raised to $247 from $218 at Wedbush
11/30/22 JPMorgan
Biogen Alzheimer's data increases approval confidence, says JPMorgan
BIIB Biogen
$304.99 /

+13.525 (+4.64%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

Conference/Events
Mizuho healthcare analysts to hold an analyst/industry conference call » 04:55
12/01/22
12/01
04:55
12/01/22
04:55
ESALY

Eisai

$70.10 /

+5.35 (+8.26%)

, BIIB

Biogen

$304.99 /

+13.525 (+4.64%)

Healthcare Analysts,…

Healthcare Analysts, along with Drs. Frank Tarazi and Friedland discuss the upcoming Clinical Trials in Alzheimer's Disease (CTAD) Meeting and Eisai and Biogen's Lecanemab in the first of two Analyst/Industry conference calls to be held on December 1.

ShowHide Related Items >><<
ESALY Eisai
$70.10 /

+5.35 (+8.26%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

ESALY Eisai
$70.10 /

+5.35 (+8.26%)

11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
11/29/22 Jefferies
Prothena data from AD/PD abstract 'promising,' says Jefferies
11/14/22 Jefferies
Biogen scarcity value goes up after Roche miss in Alzheimer's, says Jefferies
BIIB Biogen
$304.99 /

+13.525 (+4.64%)

11/30/22 Wedbush
Biogen price target raised to $247 from $218 at Wedbush
11/30/22 JPMorgan
Biogen Alzheimer's data increases approval confidence, says JPMorgan
BIIB Biogen
$304.99 /

+13.525 (+4.64%)

ESALY Eisai
$70.10 /

+5.35 (+8.26%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

ESALY Eisai
$70.10 /

+5.35 (+8.26%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

BIIB Biogen
$304.99 /

+13.525 (+4.64%)

Wednesday
Options
Early notable gainers among liquid option names on November 30th » 09:55
11/30/22
11/30
09:55
11/30/22
09:55
BIIB

Biogen

$309.62 /

+18.155 (+6.23%)

, STT

State Street

$78.46 /

+4.5 (+6.08%)

, ENPH

Enphase Energy

$311.00 /

+7.445 (+2.45%)

, EPAM

Epam Systems

$350.09 /

+6.45 (+1.88%)

, LVS

Las Vegas Sands

$45.55 /

+0.89 (+1.99%)

Notable gainers among…

Notable gainers among liquid option names this morning include Biogen (BIIB) $308.85 +17.44, State Street (STT) $78.09 +4.16, Enphase Energy (ENPH) $312.25 +8.86, EPAM Systems (EPAM) $353.92 +9.98, and Las Vegas Sands (LVS) $45.93 +1.27.

ShowHide Related Items >><<
STT State Street
$78.46 /

+4.5 (+6.08%)

LVS Las Vegas Sands
$45.55 /

+0.89 (+1.99%)

EPAM Epam Systems
$350.09 /

+6.45 (+1.88%)

ENPH Enphase Energy
$311.00 /

+7.445 (+2.45%)

BIIB Biogen
$309.62 /

+18.155 (+6.23%)

BIIB Biogen
$309.62 /

+18.155 (+6.23%)

11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
11/30/22 Wedbush
Biogen price target raised to $247 from $218 at Wedbush
11/30/22 JPMorgan
Biogen Alzheimer's data increases approval confidence, says JPMorgan
STT State Street
$78.46 /

+4.5 (+6.08%)

11/15/22 Deutsche Bank
State Street price target raised to $77 from $66 at Deutsche Bank
10/19/22 Deutsche Bank
Deutsche Bank downgrades Northern Trust to Hold after Q3 results
10/12/22 Deutsche Bank
State Street price target lowered to $66 from $70 at Deutsche Bank
09/27/22 Deutsche Bank
State Street price target lowered to $70 from $74 at Deutsche Bank
ENPH Enphase Energy
$311.00 /

+7.445 (+2.45%)

11/14/22 Deutsche Bank
Enphase Energy initiated with a Buy at Deutsche Bank
11/08/22 B. Riley
SolarEdge price target lowered to $370 from $377 at B. Riley
11/08/22 BMO Capital
SolarEdge price target raised to $316 from $306 at BMO Capital
10/26/22 B. Riley
Enphase Energy price target raised to $242 from $217 at B. Riley
EPAM Epam Systems
$350.09 /

+6.45 (+1.88%)

11/06/22 Barclays
Epam Systems price target lowered to $400 from $485 at Barclays
11/04/22 Citi
Epam Systems price target lowered to $400 from $520 at Citi
10/21/22 Piper Sandler
Epam Systems price target lowered to $419 from $460 at Piper Sandler
10/14/22 JPMorgan
Epam Systems price target lowered to $420 from $550 at JPMorgan
LVS Las Vegas Sands
$45.55 /

+0.89 (+1.99%)

11/28/22 Jefferies
Macau concession renewals removes overhang for incumbents, says Jefferies
11/28/22 JPMorgan
Las Vegas Sands price target raised to $51 from $44 at JPMorgan
11/24/22 CICC
Las Vegas Sands initiated with an Outperform at CICC
11/21/22 Morgan Stanley
Las Vegas Sands initiated with an Overweight at Morgan Stanley
STT State Street
$78.46 /

+4.5 (+6.08%)

LVS Las Vegas Sands
$45.55 /

+0.89 (+1.99%)

EPAM Epam Systems
$350.09 /

+6.45 (+1.88%)

ENPH Enphase Energy
$311.00 /

+7.445 (+2.45%)

BIIB Biogen
$309.62 /

+18.155 (+6.23%)

STT State Street
$78.46 /

+4.5 (+6.08%)

LVS Las Vegas Sands
$45.55 /

+0.89 (+1.99%)

BIIB Biogen
$309.62 /

+18.155 (+6.23%)

STT State Street
$78.46 /

+4.5 (+6.08%)

LVS Las Vegas Sands
$45.55 /

+0.89 (+1.99%)

ENPH Enphase Energy
$311.00 /

+7.445 (+2.45%)

BIIB Biogen
$309.62 /

+18.155 (+6.23%)

STT State Street
$78.46 /

+4.5 (+6.08%)

LVS Las Vegas Sands
$45.55 /

+0.89 (+1.99%)

EPAM Epam Systems
$350.09 /

+6.45 (+1.88%)

ENPH Enphase Energy
$311.00 /

+7.445 (+2.45%)

BIIB Biogen
$309.62 /

+18.155 (+6.23%)

On The Fly
Fly Intel: Pre-market Movers » 09:00
11/30/22
11/30
09:00
11/30/22
09:00
BIIB

Biogen

$291.47 /

-0.49 (-0.17%)

, HZNP

Horizon Therapeutics

$78.78 /

+0.69 (+0.88%)

, WOOF

Petco

$9.48 /

-0.185 (-1.92%)

, TITN

Titan Machinery

$34.89 /

-0.52 (-1.47%)

, DCI

Donaldson

$59.28 /

-0.44 (-0.74%)

, ENB

Enbridge

$40.86 /

-0.34 (-0.83%)

, BBW

Build-A-Bear

$19.36 /

+0.54 (+2.87%)

, XPEV

XPeng

$7.35 /

+0.44 (+6.37%)

, WDAY

Workday

$143.37 /

-1.98 (-1.36%)

, LESL

Leslie's

$15.07 /

+0.47 (+3.22%)

, HRL

Hormel Foods

$48.17 /

-0.945 (-1.92%)

, CRWD

Crowdstrike

$137.99 /

-1.6 (-1.15%)

, ASTS

AST SpaceMobile

$6.35 /

-0.01 (-0.16%)

, JNJ

Johnson & Johnson

$176.04 /

-1.26 (-0.71%)

, AMGN

Amgen

$282.00 /

-0.67 (-0.24%)

, SNY

Sanofi

$45.89 /

+0.33 (+0.72%)

, ESALY

Eisai

$64.75 /

-0.35 (-0.54%)

Check out this morning's…

ShowHide Related Items >><<
XPEV XPeng
$7.35 /

+0.44 (+6.37%)

WOOF Petco
$9.48 /

-0.185 (-1.92%)

WDAY Workday
$143.37 /

-1.98 (-1.36%)

TITN Titan Machinery
$34.89 /

-0.52 (-1.47%)

SNY Sanofi
$45.89 /

+0.33 (+0.72%)

LESL Leslie's
$15.07 /

+0.47 (+3.22%)

JNJ Johnson & Johnson
$176.04 /

-1.26 (-0.71%)

HZNP Horizon Therapeutics
$78.78 /

+0.69 (+0.88%)

HRL Hormel Foods
$48.17 /

-0.945 (-1.92%)

ESALY Eisai
$64.75 /

-0.35 (-0.54%)

ENB Enbridge
$40.86 /

-0.34 (-0.83%)

DCI Donaldson
$59.28 /

-0.44 (-0.74%)

CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

BBW Build-A-Bear
$19.36 /

+0.54 (+2.87%)

ASTS AST SpaceMobile
$6.35 /

-0.01 (-0.16%)

AMGN Amgen
$282.00 /

-0.67 (-0.24%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

11/30/22 Mizuho
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
11/30/22 Wedbush
Biogen price target raised to $247 from $218 at Wedbush
11/30/22 JPMorgan
Biogen Alzheimer's data increases approval confidence, says JPMorgan
HZNP Horizon Therapeutics
$78.78 /

+0.69 (+0.88%)

11/30/22 Cowen
Horizon Therapeutics takeout in $120-$140 range reasonable, says Cowen
11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/01/22 H.C. Wainwright
Horizon Therapeutics initiated with a Neutral at H.C. Wainwright
10/25/22 Piper Sandler
Horizon Therapeutics price target lowered to $88 from $90 at Piper Sandler
WOOF Petco
$9.48 /

-0.185 (-1.92%)

11/28/22 Wedbush
Black Friday winners Include Best Buy, losers include Pets, says Wedbush
11/28/22 Needham
Petco price target lowered to $20 from $30 at Needham
10/31/22 Citi
Petco price target lowered to $15 from $19 at Citi
10/21/22 Jefferies
Petco transferred with a Hold at Jefferies
TITN Titan Machinery
$34.89 /

-0.52 (-1.47%)

08/25/22 Baird
Titan Machinery price target raised to $34 from $27 at Baird
07/11/22 Baird
Baird trims Titan Machinery price target to $27, but 'likes' Heartland Ag deal
05/27/22 Stephens
Titan Machinery price target lowered to $41 from $44 at Stephens
05/26/22 Baird
Titan Machinery price target raised to $32 from $30 at Baird
DCI Donaldson
$59.28 /

-0.44 (-0.74%)

09/01/22 Baird
Donaldson price target lowered to $59 from $61 at Baird
07/18/22 Stifel
Donaldson price target lowered to $51 from $53 at Stifel
06/02/22 Baird
Donaldson price target lowered to $61 from $65 at Baird
03/03/22 Baird
Donaldson price target lowered to $65 from $70 at Baird
ENB Enbridge
$40.86 /

-0.34 (-0.83%)

11/07/22 National Bank
Enbridge downgraded to Sector Perform from Outperform at National Bank
10/20/22 Scotiabank
Enbridge price target lowered to C$56 from C$62 at Scotiabank
10/19/22 Morgan Stanley
Enbridge price target lowered to C$64 from C$67 at Morgan Stanley
09/12/22 Raymond James
Enbridge upgraded to Outperform from Market Perform at Raymond James
BBW Build-A-Bear
$19.36 /

+0.54 (+2.87%)

XPEV XPeng
$7.35 /

+0.44 (+6.37%)

11/28/22 Jefferies
XPeng downgraded to Underperform at Jefferies ahead of 'challenging year'
11/28/22 Jefferies
XPeng downgraded to Underperform from Hold at Jefferies
11/22/22 DBS Bank
XPeng initiated with a Buy at DBS Bank (earlier)
11/17/22 UBS
XPeng upgraded to Buy from Neutral at UBS
WDAY Workday
$143.37 /

-1.98 (-1.36%)

11/30/22 Deutsche Bank
Workday price target lowered to $215 from $230 at Deutsche Bank
11/30/22 Baird
Workday price target lowered to $223 from $235 at Baird
11/30/22 JPMorgan
Workday price target lowered to $223 from $235 at JPMorgan
11/30/22 Mizuho
Workday price target lowered to $200 from $220 at Mizuho
LESL Leslie's
$15.07 /

+0.47 (+3.22%)

11/28/22 Stifel
Leslie's price target lowered to $17 from $20 at Stifel
11/15/22 Baird
Leslie's downgraded to Neutral from Outperform at Baird
10/03/22 MKM Partners
MKM Partners starts Leslie's at Neutral, sees higher costs impact profitability
10/03/22 MKM Partners
Leslie's initiated with a Neutral at MKM Partners
HRL Hormel Foods
$48.17 /

-0.945 (-1.92%)

09/22/22 Argus
Hormel Foods price target lowered to $53 from $54 at Argus
09/02/22 Piper Sandler
Hormel Foods price target lowered to $47 from $48 at Piper Sandler
08/23/22 Stephens
Hormel Foods price target raised to $55 from $50 at Stephens
03/15/22 Goldman Sachs
Hormel Foods downgraded to Sell from Neutral at Goldman Sachs
CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

11/30/22 Needham
Crowdstrike price target lowered to $165 from $225 at Needham
11/30/22 DA Davidson
Crowdstrike price target lowered to $145 from $235 at DA Davidson
11/30/22 MKM Partners
Crowdstrike price target lowered to $190 from $200 at MKM Partners
11/30/22 Morgan Stanley
Morgan Stanley says investors should 'buy the dip' in Crowdstrike after Q3
ASTS AST SpaceMobile
$6.35 /

-0.01 (-0.16%)

11/23/22 Deutsche Bank
AST SpaceMobile price target raised to $32 from $30 at Deutsche Bank
10/28/22 B. Riley
AST SpaceMobile initiated with a Buy at B. Riley
10/19/22 Barclays
AST SpaceMobile price target lowered to $15 from $29 at Barclays
08/17/22 Deutsche Bank
AST SpaceMobile price target lowered to $30 from $31 at Deutsche Bank
JNJ Johnson & Johnson
$176.04 /

-1.26 (-0.71%)

11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
11/28/22 Morgan Stanley
Genmab risk/reward favorable into arbitration ruling, says Morgan Stanley
11/17/22 Credit Suisse
Johnson & Johnson initiated with a Neutral at Credit Suisse
AMGN Amgen
$282.00 /

-0.67 (-0.24%)

11/17/22 Credit Suisse
Amgen initiated with an Underperform at Credit Suisse
11/08/22 Oppenheimer
Amgen price target raised to $300 from $290 at Oppenheimer
11/08/22 Truist
Amgen price target raised to $280 from $266 at Truist
SNY Sanofi
$45.89 /

+0.33 (+0.72%)

11/14/22 Oppenheimer
Biogen price target raised to $315 from $300 at Oppenheimer
10/14/22 Barclays
Sanofi price target lowered to EUR 85 from EUR 105 at Barclays
10/06/22 Jefferies
Provention Bio price target raised to $15 from $10 at Jefferies
ESALY Eisai
$64.75 /

-0.35 (-0.54%)

11/29/22 Jefferies
Prothena data from AD/PD abstract 'promising,' says Jefferies
11/14/22 Jefferies
Biogen scarcity value goes up after Roche miss in Alzheimer's, says Jefferies
XPEV XPeng
$7.35 /

+0.44 (+6.37%)

WOOF Petco
$9.48 /

-0.185 (-1.92%)

WDAY Workday
$143.37 /

-1.98 (-1.36%)

TITN Titan Machinery
$34.89 /

-0.52 (-1.47%)

SNY Sanofi
$45.89 /

+0.33 (+0.72%)

LESL Leslie's
$15.07 /

+0.47 (+3.22%)

JNJ Johnson & Johnson
$176.04 /

-1.26 (-0.71%)

HZNP Horizon Therapeutics
$78.78 /

+0.69 (+0.88%)

HRL Hormel Foods
$48.17 /

-0.945 (-1.92%)

ENB Enbridge
$40.86 /

-0.34 (-0.83%)

DCI Donaldson
$59.28 /

-0.44 (-0.74%)

CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

BBW Build-A-Bear
$19.36 /

+0.54 (+2.87%)

ASTS AST SpaceMobile
$6.35 /

-0.01 (-0.16%)

AMGN Amgen
$282.00 /

-0.67 (-0.24%)

  • 30
    Nov
  • 15
    Dec
XPEV XPeng
$7.35 /

+0.44 (+6.37%)

SNY Sanofi
$45.89 /

+0.33 (+0.72%)

JNJ Johnson & Johnson
$176.04 /

-1.26 (-0.71%)

HZNP Horizon Therapeutics
$78.78 /

+0.69 (+0.88%)

HRL Hormel Foods
$48.17 /

-0.945 (-1.92%)

ENB Enbridge
$40.86 /

-0.34 (-0.83%)

CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

ASTS AST SpaceMobile
$6.35 /

-0.01 (-0.16%)

AMGN Amgen
$282.00 /

-0.67 (-0.24%)

XPEV XPeng
$7.35 /

+0.44 (+6.37%)

WOOF Petco
$9.48 /

-0.185 (-1.92%)

WDAY Workday
$143.37 /

-1.98 (-1.36%)

TITN Titan Machinery
$34.89 /

-0.52 (-1.47%)

SNY Sanofi
$45.89 /

+0.33 (+0.72%)

JNJ Johnson & Johnson
$176.04 /

-1.26 (-0.71%)

HZNP Horizon Therapeutics
$78.78 /

+0.69 (+0.88%)

HRL Hormel Foods
$48.17 /

-0.945 (-1.92%)

ESALY Eisai
$64.75 /

-0.35 (-0.54%)

CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

ASTS AST SpaceMobile
$6.35 /

-0.01 (-0.16%)

AMGN Amgen
$282.00 /

-0.67 (-0.24%)

XPEV XPeng
$7.35 /

+0.44 (+6.37%)

WDAY Workday
$143.37 /

-1.98 (-1.36%)

SNY Sanofi
$45.89 /

+0.33 (+0.72%)

LESL Leslie's
$15.07 /

+0.47 (+3.22%)

JNJ Johnson & Johnson
$176.04 /

-1.26 (-0.71%)

ENB Enbridge
$40.86 /

-0.34 (-0.83%)

CRWD Crowdstrike
$137.99 /

-1.6 (-1.15%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

ASTS AST SpaceMobile
$6.35 /

-0.01 (-0.16%)

AMGN Amgen
$282.00 /

-0.67 (-0.24%)

Recommendations
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation » 08:13
11/30/22
11/30
08:13
11/30/22
08:13
BIIB

Biogen

$291.47 /

-0.49 (-0.17%)

, ESALY

Eisai

$64.75 /

-0.35 (-0.54%)

Mizuho analyst Salim Syed…

Mizuho analyst Salim Syed points out that the name "Biogen" was not mentioned during last night's 90 minute presentation on the detailed Phase 3 results for lecanemab. Biogen (BIIB) is clearly a partner to Eisai (ESLAY) in the lecanemab program, but no where during the presentation was "Biogen" uttered, Syed tells investors in a research note. "I do wonder if this alone will put pressure on Biogen stock today, and whether it signals a growing possibility of an oncoming litigation between the partners," writes the analyst. Syed adds that the presentation was as expected, "meaning the data overall continued to look great, and any 'holes' were in the subgroup analyses." He believes none of these are likely to tank the thesis that the drug will get approved and used, assuming reimbursement. Syed has a Buy rating on Biogen with a $325 price target. The stock in premarket trading is up 3% to $300.15.

ShowHide Related Items >><<
ESALY Eisai
$64.75 /

-0.35 (-0.54%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

11/30/22 Jefferies
Biogen price target raised to $350 from $325 at Jefferies
11/30/22 Wedbush
Biogen price target raised to $247 from $218 at Wedbush
11/30/22 JPMorgan
Biogen Alzheimer's data increases approval confidence, says JPMorgan
11/30/22 Barclays
Biogen price target raised to $313 from $275 at Barclays
ESALY Eisai
$64.75 /

-0.35 (-0.54%)

11/29/22 Jefferies
Prothena data from AD/PD abstract 'promising,' says Jefferies
11/14/22 Jefferies
Biogen scarcity value goes up after Roche miss in Alzheimer's, says Jefferies
10/25/22 Piper Sandler
Piper 'comfortable on the sidelines' of Biogen after 'largely cosmetic beat'
BIIB Biogen
$291.47 /

-0.49 (-0.17%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

ESALY Eisai
$64.75 /

-0.35 (-0.54%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

Recommendations
Biogen price target raised to $350 from $325 at Jefferies » 08:04
11/30/22
11/30
08:04
11/30/22
08:04
BIIB

Biogen

$291.47 /

-0.49 (-0.17%)

, ESALY

Eisai

$64.75 /

-0.35 (-0.54%)

Jefferies analyst Michael…

Jefferies analyst Michael Yee raised the firm's price target on Biogen (BIIB) to $350 from $325 and keeps a Buy rating on the shares after the company and partner Eisai (ESALY) presented the full Phase 3 lecanemab data at CTAD. The presentations at CTAD "showed clear positive efficacy and no major concerns on safety," according to Yee, who came away from the presentation with "comfort the data are clean, and importantly any major risk is removed and the overhang shall now pass." Given his view that long-term investors are "more likely to become bullish and get involved" following the presentations, Yee contends that Biogen's stock "can go higher" from here.

ShowHide Related Items >><<
ESALY Eisai
$64.75 /

-0.35 (-0.54%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

11/30/22 Wedbush
Biogen price target raised to $247 from $218 at Wedbush
11/30/22 JPMorgan
Biogen Alzheimer's data increases approval confidence, says JPMorgan
11/30/22 Barclays
Biogen price target raised to $313 from $275 at Barclays
11/30/22 Piper Sandler
Piper keeps lecanemab thesis after full data presentation
ESALY Eisai
$64.75 /

-0.35 (-0.54%)

11/29/22 Jefferies
Prothena data from AD/PD abstract 'promising,' says Jefferies
11/14/22 Jefferies
Biogen scarcity value goes up after Roche miss in Alzheimer's, says Jefferies
10/25/22 Piper Sandler
Piper 'comfortable on the sidelines' of Biogen after 'largely cosmetic beat'
10/24/22 Jefferies
Biogen price target raised to $325 from $300 at Jefferies
BIIB Biogen
$291.47 /

-0.49 (-0.17%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

ESALY Eisai
$64.75 /

-0.35 (-0.54%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

Recommendations
Biogen price target raised to $247 from $218 at Wedbush » 07:30
11/30/22
11/30
07:30
11/30/22
07:30
BIIB

Biogen

$291.47 /

-0.49 (-0.17%)

Wedbush analyst Laura…

Wedbush analyst Laura Chico raised the firm's price target on Biogen to $247 from $218 and keeps a Neutral rating on the shares. The analyst notes detailed Phase 3 lecanemab data were presented concurrently at CTAD and in the New England Journal of Medicine. Detailed results were largely as advertised with consistent improvements across various AD scales/measures. Subgroup analyses depict certain divergences on response outcomes, but not enough to derail a potential approval in her view. Chico thinks the data reinforces the likelihood of a potential lecanemab approval. What keeps her cautious is the need for broader reimbursement via CMS.

ShowHide Related Items >><<
BIIB Biogen
$291.47 /

-0.49 (-0.17%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

11/30/22 JPMorgan
Biogen Alzheimer's data increases approval confidence, says JPMorgan
11/30/22 Barclays
Biogen price target raised to $313 from $275 at Barclays
11/30/22 Piper Sandler
Piper keeps lecanemab thesis after full data presentation
11/29/22 Jefferies
Prothena data from AD/PD abstract 'promising,' says Jefferies
BIIB Biogen
$291.47 /

-0.49 (-0.17%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

Recommendations
Biogen Alzheimer's data increases approval confidence, says JPMorgan » 07:14
11/30/22
11/30
07:14
11/30/22
07:14
BIIB

Biogen

$291.47 /

-0.49 (-0.17%)

, LLY

Eli Lilly

$363.94 /

-1.685 (-0.46%)

JPMorgan analyst Chris…

JPMorgan analyst Chris Schott says Biogen (BIIB) presented full data from the lecanemab Phase 3 CLARITY-AD study with overall results consistent with the positive headlines results from the trial. He expects a continued debate on the magnitude of benefit seen with lecanemab but says the drug's impact to patients appears highly consistent along all measurable endpoints "that clearly improved over time." The full data should increase confidence in the likelihood of full approval and reimbursement for lecanemab, Schott tells investors in a research note. He expects Biogen shares, and to a lesser extent Eli Lilly (LLY), shares to react favorably to the results. The CLARITY-AD results continue to support a high probability of success for Eli Lilly's donanemab, contends Schott.

ShowHide Related Items >><<
LLY Eli Lilly
$363.94 /

-1.685 (-0.46%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

11/30/22 Barclays
Biogen price target raised to $313 from $275 at Barclays
11/30/22 Piper Sandler
Piper keeps lecanemab thesis after full data presentation
11/29/22 Jefferies
Prothena data from AD/PD abstract 'promising,' says Jefferies
11/29/22 Mizuho
Cerebral amyloid angiopathy new risk for beta-amyloid space, says Mizuho
LLY Eli Lilly
$363.94 /

-1.685 (-0.46%)

11/22/22 Berenberg
Eli Lilly price target raised to $375 from $345 at Berenberg
11/17/22 Credit Suisse
Eli Lilly initiated with an Outperform at Credit Suisse
11/15/22 Truist
Eli Lilly price target raised to $421 from $400 at Truist
LLY Eli Lilly
$363.94 /

-1.685 (-0.46%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

LLY Eli Lilly
$363.94 /

-1.685 (-0.46%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

LLY Eli Lilly
$363.94 /

-1.685 (-0.46%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

LLY Eli Lilly
$363.94 /

-1.685 (-0.46%)

BIIB Biogen
$291.47 /

-0.49 (-0.17%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.